Coronavirus (COVID-19)
Learn more
August 11, 2010
Patients will be randomly selected for either ablation or drug therapy, neither of which is experimental, and will receive follow-up care every six months for two years. Participants in the study must be more than 18 years old, have AF that is serious enough to warrant active therapy, and be eligible for both catheter ablation and anti-arrhythmia drugs. Patients interested in participating in the study or obtaining further information can click here or contact Ellen Volponi at 860.545.3416 or Ellen.Volponi@hhchealth.org.
Phone: 860.545.3416
Email: Ellen.Volponi@hhchealth.org
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.